Application No.: 10/577,462 Docket No.: 14090-00004-US1

REMARKS

Claims 81-82, 97-98, and 102-147 are pending. Claims 80, 83-96, and 99-101 have been cancelled without prejudice or disclaimer and applicants reserve the right to pursue the cancelled subject matter in the future. Claim 81 has been amended without prejudice or disclaimer to include the recitations of cancelled claim 99. Claim 82 has been amended to remove definitions, which are no longer necessary in view of the amendment to claim 81. Claim 97 has been amended so the "n" of formula "–(CH₂)_n—" is an integer from "3 to 7". Support for this amendment is located on page 15, line 18 of the specification where it lists BAZL as "— (CH₂)₇—, — (CH₂)₆—, — (CH₂)₅—, — (CH₂)₄—, — (CH₂)₃—". Claim 98 has been amended to correct a typographical error. The term "BAZ" was corrected to properly read, "BAZL". Claims 115 has been amended to correct its dependency from cancelled claim 80 and to remove two compounds. Claims 116-118, 122, 127, 129, 131-132, 134, 137-138, and 143 have been amended to correct their dependency in view of the cancellation of claim 80. No new matter has been added into the claims.

Response to the Requirement for Restriction and Election of Species

In the Requirement for Restriction set forth in the Office Action mailed January 29, 2008, the Examiner required restriction between:

Group I Claims 80-117, drawn to compounds and pharmaceutical compositions; and

Group II Claims 118-147, drawn to various methods of using the compounds and pharmaceutical compositions of claims 80-117.

Applicant hereby elect Group I (pending claims 81-82, 97-98, and 102-117) for continued examination.

The Office Action also instructs applicants to elect a single disclosed species for searching purposes to which the claims will be restricted if no generic claim is finally held allowable.

Applicant hereby elect the species <u>6-(3-Benzoyl-ureido)-hexanoic acid hydroxyamide</u>, shown below, which is presented on page 75 of the specification as Example 10 and specifically claimed in claim 115.

Applicants note that the elected species reads upon elected claims 81-82, 97-98, 102-103, 106-108, and 110-117, many of which are generic claims. Upon the allowance of a generic claim, applicant is entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR § 1.141.

Finally, upon allowance of elected subject matter (*i.e.*, claims directed to compounds and pharmaceutical compositions), applicants exercise their right to rejoinder of claims 118-147 directed to methods of using the compounds and pharmaceutical compositions of the elected claims. MPEP § 821.04(b). In preparation for rejoinder, applicants have amended non-elected claims 118, 122, 127, 129, 131-132, 134, 137-138, and 143 to correct their dependency in view of the cancellation of claim 80.

Application No.: 10/577,462 Docket No.: 14090-00004-US1

A five-month extension of time and its corresponding fee is being submitted concurrently with this response. Applicants believe that no additional fees are due at this time. However, if a fee is due, please charge our Deposit Account No. 22-0185, under Order No. 14090-00004-US1 from which the undersigned is authorized to draw.

Dated: July 24, 2008 Respectfully submitted,

By: /R. James Balls/

Mark J. Pino

Registration No.: 43,858

R. James Balls

Registration No.: 57,703

CONNOLLY BOVE LODGE & HUTZ LLP

1875 Eye Street, NW

Suite 1100

Washington, DC 20006

(202) 331-7111

(202) 293-6229 (Fax)

Attorneys for Applicant